Hoppa till innehållet
Organic sales growth:
Q4, 2023: 29% (-17)
EBITDA margin:
Q4, 2023: 36% (32)
October 1 – December 31, 2023
Net sales increased by 32% (-7) to SEK 201 m (152).
Sales increased organically by 29% (-17), currency effect 3% (10).
EBITDA increased to SEK 73 m (48).
EBITDA margin amounted to 36% (32).
Profit before tax increased to SEK 63 m (40).
Earnings per share before and after dilution increased to SEK 2.11 (1.35).
Cash flow from operating activities increased to SEK 76 m (28).
The Board of Directors proposes a dividend of SEK 2.25 per share for 2023 (2.25).
Significant events after the period close
CellaVision and Sysmex Corporation (“Sysmex”) have announced a Strategic Alliance Agreement to reinforce and extend their joint leadership position within hematology and seize new opportunities for optimized diagnostics.